A 58-year-old woman from urban Delhi attends a workplace health screening programme. She is found to have a BP of 152/96 mmHg (repeat reading 150/94 mmHg), fasting glucose 126 mg/dL, LDL cholesterol 145 mg/dL, HDL cholesterol 38 mg/dL, and triglycerides 180 mg/dL. She has a 10-year history of type 2 diabetes mellitus and is currently on metformin alone. She denies chest pain, dyspnoea, or palpitations. Her 10-year absolute CVD risk using the Indian CVD risk calculator is 18%. What is the most appropriate next step in management?

Explanation

## Absolute CVD Risk Assessment and Pharmacotherapy Initiation **Key Point:** An absolute 10-year CVD risk of ≥15% in an asymptomatic individual warrants initiation of pharmacotherapy for risk factor modification, regardless of individual risk factor levels, because the cumulative risk exceeds the threshold for intervention. ## Risk Stratification Interpretation **High-Yield:** The Indian CVD risk calculator stratifies patients into: - Low risk: <10% 10-year CVD risk - Moderate risk: 10–15% 10-year CVD risk - High risk: 15–20% 10-year CVD risk - Very high risk: >20% 10-year CVD risk This patient's 18% risk places her in the **high-risk category**, which mandates pharmacotherapy initiation. ## Management Algorithm for High-Risk Asymptomatic Patients ```mermaid flowchart TD A[Asymptomatic patient with CVD risk factors]:::outcome --> B{Calculate 10-year absolute CVD risk}:::decision B -->|<10%| C[Lifestyle counselling only]:::action B -->|10-15%| D[Lifestyle + consider pharmacotherapy]:::action B -->|≥15%| E[Initiate pharmacotherapy + lifestyle]:::action E --> F[Antihypertensive: Target BP <140/90]:::action E --> G[Statin: Atorvastatin 40-80 mg daily]:::action E --> H[Optimize diabetes control: HbA1c <7%]:::action F --> I[Reassess at 3 months]:::outcome G --> I H --> I ``` ## Pharmacotherapy Targets for This Patient | Risk Factor | Current Value | Target | Recommended Drug | |---|---|---|---| | BP | 150/94 mmHg | <140/90 mmHg | ACE-I or ARB (cardioprotective in diabetes) | | LDL cholesterol | 145 mg/dL | <100 mg/dL (high-risk) | Atorvastatin 40–80 mg daily | | Fasting glucose | 126 mg/dL | 100–130 mg/dL | Optimize metformin or add second agent | | Triglycerides | 180 mg/dL | <150 mg/dL | Fibrate if needed after statin | **Clinical Pearl:** In a diabetic patient with hypertension and dyslipidaemia, an ACE inhibitor or ARB is preferred as the first-line antihypertensive because of renal and cardioprotective benefits. Statin therapy is indicated regardless of LDL level in all diabetic patients aged >40 years with additional CVD risk factors. **Warning:** Do NOT delay pharmacotherapy in a patient with 18% absolute CVD risk simply because she is asymptomatic. Absolute risk assessment overrides individual risk factor thresholds in determining treatment decisions.